Navigation Links
Genmab Announces Details of Planned Ofatumumab Phase II Study in Multiple Sclerosis
Date:12/13/2007

Summary: Genmab has Announced Details of a Planned Phase II Study of

Ofatumumab to Treat Relapsing Remitting Multiple Sclerosis

COPENHAGEN, Denmark, December 13 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today details of a planned Phase II study of ofatumumab (HuMax-CD20(R)) for the treatment of relapsing remitting multiple sclerosis (RRMS). Approximately 324 patients will be enrolled in the study which will be conducted under Genmab's collaboration with GlaxoSmithKline (GSK). The study is expected to begin in the first quarter of 2008.

Ofatumumab is an investigational, fully human, next generation monoclonal antibody that targets a unique epitope of the CD20 receptor on the surface of B-cells. Other anti-CD20 antibodies currently available or in development bind to a different epitope on the CD20 receptor. Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and GlaxoSmithKline.

"Multiple sclerosis is a debilitating disease for which there are currently few treatments," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We hope our fully human antibody, ofatumumab, may offer another potential treatment option for patients suffering from this incapacitating disease."

About the trial

The double blind randomized trial will consist of two parts. Part A will include approximately 36 patients in one of three increasing dose cohorts (100 mg, 300 mg or 700 mg of ofatumumab) randomized to receive ofatumumab or placebo. An independent data monitoring committee (IDMC) will evaluate the safety of each sequential cohort prior to progression to the next cohort. When all patients in Part A have had their week 4 MRI scan, the IDMC will evaluate the data before Part B of the study begins.

Part B will consist of a 48 week treatment period of approximately 288 patients. Patients will be randomized to treatment with 100 mg, 300 mg, or 700 mg of ofatu
'/>"/>

SOURCE Genmab A/S
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 A major challenge before new ... dense realm of Boston-Cambridge, is gaining visibility that can ... Sherley, the Director of Boston’s Adult Stem Cell Technology ... national visibility of his company an important priority since ... addition to a social media marketing campaign ...
(Date:8/28/2014)... 2014 “This kit has an improved extraction ... 0 to 150 ppb,” said Mark Tess, PhD, Mycotoxin Product ... to plant owners and USDA-GIPSA inspection agencies that have a ... can take place in a matter of minutes with nothing ... test the feed and grain before accepting it, but they ...
(Date:8/28/2014)... -- Next month, executives from clinical trial marketing firm BBK Worldwide ... Patient-Centered Clinical Trials 2014 , to be held at ... September 4-5. Patient recruitment experts Bonnie A. Brescia , ... share insights on the benefits of employing an effective patient ... media to mobile apps – can be used to drive ...
(Date:8/28/2014)... BELLINGHAM, Washington, USA (PRWEB) August 27, 2014 ... Colorado next month for SPIE Laser Damage 2014 ... on optical materials for high-power lasers will run 14-17 ... international society for optics and photonics . , The ... key for understanding laser damage to optical materials will ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4BBK Worldwide Leads Sessions at Key September Events 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3
... May 11, 2011 Reportlinker.com announces that a ... catalogue: Healthcare Information Technology ... REPORT HIGHLIGHTS * ... healthcare IT technologies covered in this report at ...
... OncoSec Medical Inc. (OTCBB: ONCS), a therapeutic oncology ... tumor cancers that have unmet medical needs, announced ... leadership team. Formed earlier this year, OncoSec expects ... tumor-destroying, tissue-sparing ElectroOncology therapies before the end of ...
... CHICAGO, IL (May 7, 2011) Research being ... while there are significantly increased benefits for qualifying ... and outcomes need to be considered when determining ... is the largest international gathering of physicians and ...
Cached Biology Technology:Reportlinker Adds Healthcare Information Technology 2Reportlinker Adds Healthcare Information Technology 3Reportlinker Adds Healthcare Information Technology 4Reportlinker Adds Healthcare Information Technology 5Reportlinker Adds Healthcare Information Technology 6Reportlinker Adds Healthcare Information Technology 7Reportlinker Adds Healthcare Information Technology 8Reportlinker Adds Healthcare Information Technology 9Reportlinker Adds Healthcare Information Technology 10Reportlinker Adds Healthcare Information Technology 11OncoSec Announces Leadership Team Appointments 2OncoSec Announces Leadership Team Appointments 3OncoSec Announces Leadership Team Appointments 4New approaches, technological advances offer promise for obesity treatment 2
(Date:8/29/2014)... from the University of Texas Medical Branch at Galveston has ... antibodies can completely protect monkeys against a lethal dose of ... time when the disease is severe. , Thomas Geisbert, professor ... Nature discussing advances in Ebola treatment research. The filoviruses ... most deadly of pathogens, with fatality rates of up to ...
(Date:8/29/2014)... prolific bloomer Emiliania huxleyi , can grow without ... contradicts the common view that E. huxleyi ... of thiamine in the ocean to survive. , "It,s ... says CIFAR Senior Fellow Alexandra Worden , co-author ... fellows John Archibald (Dalhousie University), Adrin ...
(Date:8/28/2014)... (ESA) is pleased to announce the selection of Dr. ... Honorary Membership acknowledges those who have served ESA for ... affairs of the Society that has reached an extraordinary ... ESA Governing Board and then voted on by the ... Awards Ceremony at Entomology 2014, ESA,s Annual Meeting in ...
Breaking Biology News(10 mins):Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3Fred Baxendale selected as Honorary Member of the Entomological Society of America 2
... VANCOUVER, BC John Balbus, MD, MPH, Senior ... Environmental Health Sciences (NIEHS), will discuss the significant public ... how children around the world may be affected. Dr. ... Face On Climate Change: A Public Health Perspective," ...
... NOAA and Texas A&M UniversityCorpus Christi were astounded to find ... some of the most common ocean habitats in the world. ... previous beliefs about the prevalence of seamounts, which are treasure ... reefs, most people will never see a seamount, but this ...
... Current research suggests that tumor-secreted exosomes inhibit the ... by Liu et al, "Contribution of MyD88 to the ... in the May 2010 issue of The American ... a critical role in identifying and destroying tumor cells. ...
Cached Biology News:Climate change and its impact on human health 2Scientists identify seamounts as significant, unexplored territory 2
... Antigen sequence: H-Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH 2 ... our corresponding peptide and ... 5 I-labelled peptide, ... (H-1470) and ([ 1 ...
... ProteinPilot Software enables you to ... Now you can distinguish protein isoforms, ... You can also visualize peptide-protein associations ... ideal for protein identification and relative ...
... Motic's B3 series of microscopes offer all ... required for laboratory work. Equipped with Koehler ... Contrast (ASC) objectives. The B3 is the ... Siedentopf binocular tube eliminates the need for ...
... RNA gel stain is a sensitive ... fluorescence when bound to RNA and low ... use with either formaldehyde/agarose or polyacrylamide gels ... A 500 µL unit size (S-7564) and ...
Biology Products: